drugset / Trial / NCT03994107
Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
Phase 1/2
Unknown
40 enrolled
Peking Union Medical College
CSPC Ouyi Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of pegylated liposomal doxorubicin（PLD）plus Albumin-Bound Paclitaxel and trastuzumab as neoadjuvant therapy in HER-2 positive breast cancer.
Timeline
- Start
- 2019-10-01
- Primary completion
- 2021-01-01
- Completion
- 2021-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin-Bound Paclitaxel | Unknown | 260 mg/m2 | Intravenous |
| Subject | Pegylated liposomal doxorubicin | Unknown | 30 mg/m2 | Intravenous |
| Subject | Pegylated liposomal doxorubicin | Unknown | 35 mg/m2 | Intravenous |
| Subject | Pegylated liposomal doxorubicin | Unknown | 40 mg/m2 | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |